Drug Trial Radar · NCT07250802
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
210
Planned (sponsor's estimate)
Start
Dec 4, 2025
Primary completion
Jul 3, 2034
Study completion Jul 3, 2034
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Nov 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 4 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main aim of this study is to see how well the medicine zasocitinib works, how safe it is, and how children and teenagers aged 4 to under 18 with moderate-to-severe plaque psoriasis respond to it. The study will be done in 2 parts: Part A will include both children and teenagers, while part B will only include children. At first, only teenagers who meet the study rules can participate in this study. Children may only start to participate in Part A Cohort 2 once enough information has been collected from Part B to determine the appropriate dose. Participants in Part A will initially be assigned to receive either zasocitinib or placebo for the first 16 weeks of treatment, then all participants will receive zasocitinib through the end of the study. All participants in Part B will be assigned to receive treatment with zasocitinib throughout the study. Participants will be in the study for up to 4 years and 2 months (217 weeks), including up to 35 days for the screening period, 208 weeks of treatment (Part A and Part B) and a 4-week safety follow-up period. During the study, participants will visit their study site multiple times.
Conditions
- Plaque Psoriasis
Interventions
ZasocitinibDrug
Zasocitinib.
PlaceboDrug
Zasocitinib matching placebo.
ZasocitinibDrug
Zasocitinib.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Percentage of Participants Achieving a Static Physician's Global Assessment (sPGA) of Clear (0) or Almost Clear (1) With a Greater than or Equal to (>=) 2-Point Decrease From Baseline at Week 16Time frame: At Week 16
- Part A: Percentage of Participants Achieving >= 75 Percent (%) Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 16Time frame: At Week 16
- Part B: Maximum Observed Plasma Concentration (Cmax) of ZasocitinibTime frame: Pre-dose and Post-dose on Day 7
- Part B: Time to Maximum Concentration (Tmax) of ZasocitinibTime frame: Pre-dose and Post-dose on Day 7
- Part B: Area Under the Concentration-Time Curve From Time 0 to the Time of Last Quantifiable Concentration (AUC0-Last) of ZasocitinibTime frame: Pre-dose and Post-dose on Day 7
Locations
38 sites in 7 countries. Site status is shown where the registry gives one.
Exalt Clinical Research
Chula Vista, California · Recruiting
First OC Dermatology Research Inc.
Fountain Valley, California · Recruiting
Direct Helpers Medical Center
Hialeah, Florida · Recruiting
Arlington Dermatology
Rolling Meadows, Illinois · Recruiting
Apex Clinical Research Center, LLC
Canton, Ohio · Recruiting
Wright State Physicians
Fairborn, Ohio · Recruiting
Apex Clinical Research Center, LLC
Mayfield Heights, Ohio · Recruiting
Medical University of South Carolina
Charleston, South Carolina · Recruiting
UT Physicians Dermatology - Bellaire Station
Bellaire, Texas · Recruiting
Texas Dermatology and Laser Specialists-San Antonio
San Antonio, Texas · Recruiting
Medical College of Wisconsin
Milwaukee, Wisconsin · Recruiting
Peking University Third Hospital
Beijing, China · Recruiting
Huashan Hospital Fudan University
Shanghai, China · Recruiting
Beijing Children Hospital, Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
Dermatology Hospital of Southern Medical University
Guangzhou, Guangdong, China · Recruiting
Hunan Children's Hospital
Changsha, Hunan, China · Recruiting
Hangzhou First People's Hospital
Hangzhou, Zhejiang, China · Recruiting
Universitätsklinikum Bonn
Bonn, Germany · Recruiting
Fachklinik Bad Bentheim
Bad Bentheim, Lower Saxony, Germany · Recruiting
Uniklinik Koln, Klinik fur Dermatologie und Venerologie
Cologne, North Rhine-Westphalia, Germany · Recruiting
University Hospital of Muenster
Münster, North Rhine-Westphalia, Germany · Recruiting
Universita Degli Studi Di Padova
Padova, Italy · Recruiting
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Rome, Italy · Recruiting
Presidio Ospedaliero Gaspare Rodolico
Catania, Sicily, Italy · Recruiting
Nagoya City University Hospital
Nagoya, Aichi-ken, Japan · Recruiting
Hospital of the University of Occupational and Environmental Health, Japan
Kitakyushu-shi, Fukuoka, Japan · Recruiting
Mie University Hospital
Tsu, Mie, Mie-ken, Japan · Recruiting
Nippon Life Hospital
Osaka, Osaka, Japan · Recruiting
Teikyo University Hospital
tabashi City, Tokyo, Japan · Recruiting
"DERMED" Centrum Medyczne Sp. z o. o.
Lodz, Poland · Recruiting
Dermoklinika-Centrum Medyczne s.c
Lodz, Poland · Recruiting
Cityclinic Przychodnia lekarsko psychologiczna Matusiak sp.p
Wroclaw, Lower Silesian Voivodeship, Poland · Recruiting
Luxderm Specjalistyczny Gabinet Dermatologiczny Dorota Krasowska
Lublin, Lublin Voivodeship, Poland · Recruiting
Uniwersytecki Szpital Kliniczny im. Fryderyka Chopina w Rzeszowie
Rzeszów, Podkarpackie Voivodeship, Poland · Recruiting
Centrum Badan Klinicznych Pi-house Sp. Z O. O.
Gdansk, Pomeranian Voivodeship, Poland · Recruiting
Hospital de La Santa Creu i Sant Pau - Dermatologia
Barcelona, Spain · Recruiting
Hospital Universitario 12 de Octubre
Madrid, Spain · Recruiting
Complejo Hospitalario Universitario de Santiago de Compostela
Santiago de Compostela, A Coruna, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.